Werewolf Therapeutics, Inc. (HOWL)

Market Cap	47.12M
Revenue (ttm)	1.14M
Net Income (ttm)	-72.41M
Shares Out	44.87M
EPS (ttm)	-1.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	387,681
Open	1.070
Previous Close	1.090
Day's Range	1.025 - 1.119
52-Week Range	0.595 - 4.180
Beta	0.66
Analysts	Strong Buy
Price Target	8.33 (+693.33%)
Earnings Date	Aug 7, 2025

About HOWL

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatm...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 2021
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: HOWL
• Website: https://werewolftx.com

Financial Performance

In 2024, Werewolf Therapeutics's revenue was $1.89 million, a decrease of -90.55% compared to the previous year's $19.94 million. Losses were -$70.52 million, 88.7% more than in 2023.

Analyst Summary

According to 3 analysts, the average rating for HOWL stock is "Strong Buy." The 12-month stock price target is $8.33, which is an increase of 693.33% from the latest price.

Price Target

$8.33

(693.33% upside)

Analyst Consensus: Strong Buy